Whitney Domico

Professor Hansen

BIO247

17 October 2022

Project Proposal

*Introduction*

Schizophrenia is a mental disorder that affects roughly 1% of the population [1]. It is characterized by two or more of the following: delusions, hallucinations, disorganized speech, and catatonia. Schizophrenia usually manifests in a patient’s late adolescence or young adulthood [2] and is currently incurable and, for some patients, untreatable.

Unfortunately, the mechanisms surrounding the disorder are vastly unknown. The “original dopamine hypothesis” states that schizophrenia may be caused by an overabundance of dopamine in the cerebral fluid; however, it is now widely accepted that this, if true, can not possibly be the entire story [3]. Unfortunately, the first-line treatment for schizophrenia are antipsychotics, all of which target the type-ii-dopaminergic receptor [1]. While these treatments do appear to work well for some patients, there are a significant number that respond only slightly or not at all. For these patients, it is overwhelmingly important that other causes for this disorder are discovered and published so that other treatments may be introduced.

Specifically, the *N*-methyl-D-aspartate (NMDA) receptor is one that is beginning to get more attention. Some researchers believe that this receptor’s hypofunction may be a key contributor to schizophrenia symptoms. A few articles cite the glycine modulatory site (GMS), a regulator of the NMDA receptor, as another potential target. Overall, though, there is not an obvious/agreed upon pathway for this mechanism [4].

Another potential route of research is looking into identifying the loci associated with schizophrenia. Currently, there are around 100 identified loci [1]; however, there are disagreements among the research community about which of these are specific to schizophrenia or significant to treatment at all. These loci are important because they may be able to pinpoint the specific location of singular nucleotide polymorphisms (SNPs) in schizophrenia patients, and this information can be used in further research to identify the implications and genetic transmissibility of those particular mutations. Also, schizophrenia is understood to be hereditary [5]; however, it is not clear which genes are the ones responsible or even if there is solely a genetic cause. Therefore, even identifying a way to predict the development of schizophrenia may be very helpful in the field.

For both of these approaches, better understanding could lead to both preventative treatments and/or symptom management for those suffering from this schizophrenia.

*Proposed Project*

For my project, I have not decided on whether I want to focus on the loci for schizophrenia or the NMDA pathway; however, it seems that there is a significant overlap in the research anyway and so I may be able to delve into both. I expect that when I start actually performing manipulations of the data that I will more easily be able to decide which route I want to explore deeper.

I began collecting articles that I judged to be relevant to this project. Some were meta-analyses, and for these ones I also retrieved some articles that they cited in their supplementary data. From these, I determined which articles were available on *PubMed Central*, and I discarded the ones that were not (because I intend to use Pr. Hansen’s machine reader which uses PMCIDs). I also did a reassessment of the remaining articles and discarded some that I believed no longer fit into either the NMDA or loci categories.

Here are the PMCIDs of the papers that I expect to be using:

[PMC34453](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC34453)

[PMC3910086](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910086)

[PMC3077530](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077530)

[PMC2775422](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775422)

[PMC3912837](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912837)

[PMC2890845](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890845)

[PMC3603134](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603134)

[PMC4724864](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724864)

[PMC6927206](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927206)

[PMC3872086](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872086)

[PMC3923972](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972)

[PMC3827979](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827979)

[PMC4059435](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059435)

[PMC3905728](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905728)

[PMC3905227](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905227)

[PMC5518924](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518924)

Using these papers, I intend to first run them through the aforementioned machine reader and see if any obvious patterns emerge. For the ones pertaining to loci, I expect that I will utilize primarily the visualization techniques in R to create density graphs. I also may attempt to do a discretization of the loci into the chromosomes that they are on and then output a density plot that highlights this. If there is a chromosome with a significant number of loci, I may go deeper into this one and see if there are any specific areas that are particularly dense.

For the NMDA papers, I downloaded OmniPath [7] onto my computer because it seems that it may be useful in creating an igraph and/or map of the pathway. I want to expand this diagram to a detailed but still useful level, and I think that OmniPath seems to be a good choice for this. Pathview [8] is another choice that I am looking forward to experimenting with, and I expect that at least one – or maybe both – of these will help create a useful visualization. I believe that I want to focus more on the regulatory aspects of the pathway, which I believe are sometimes ignored in favor of the overall design.

Overall, I am hoping that this project helps in organizing the current research that is being performed in the area of schizophrenia and related psychotic illnesses.

References

\*\* References 1-8 are citied in proposal; 9-22 correspond to aforementioned PMCIDs

[1]

Schizophrenia Working Group of the Psychiatric Genomics Consortium, “Biological insights from 108 schizophrenia-associated genetic loci,” *Nature*, vol. 511, no. 7510, pp. 421–427, Jul. 2014, doi: [10.1038/nature13595](https://doi.org/10.1038/nature13595).

[2]

V. Trubetskoy *et al.*, “Mapping genomic loci implicates genes and synaptic biology in schizophrenia,” *Nature*, vol. 604, no. 7906, pp. 502–508, Apr. 2022, doi: [10.1038/s41586-022-04434-5](https://doi.org/10.1038/s41586-022-04434-5).

[3]

Genetic Risk and Outcome in Psychosis (GROUP) *et al.*, “Common variants conferring risk of schizophrenia,” *Nature*, vol. 460, no. 7256, pp. 744–747, Aug. 2009, doi: [10.1038/nature08186](https://doi.org/10.1038/nature08186).

[4]

D. T. Balu, “The NMDA Receptor and Schizophrenia,” in *Advances in Pharmacology*, vol. 76, Elsevier, 2016, pp. 351–382. doi: [10.1016/bs.apha.2016.01.006](https://doi.org/10.1016/bs.apha.2016.01.006).

[5]

P. V. Gejman, A. R. Sanders, and J. Duan, “The Role of Genetics in the Etiology of Schizophrenia,” *Psychiatric Clinics of North America*, vol. 33, no. 1, pp. 35–66, Mar. 2010, doi: [10.1016/j.psc.2009.12.003](https://doi.org/10.1016/j.psc.2009.12.003).

[6]

“A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation - PMC.” <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972/?report=printable> (accessed Oct. 15, 2022).

[7]

Denes Turei, “OmniPath: guidelines and gateway for literature-curated signaling pathway resources,” *Nature Methods*, vol. 13, pp. 966–967, Nov. 2016, doi: <https://doi.org/10.1038/nmeth.4077>.

[8]

W. Luo and C. Brouwer, “Pathview: an R/Bioconductor package for pathway-based data integration and visualization,” *Bioinformatics*, vol. 29, no. 14, pp. 1830–1831, Jul. 2013, doi: [10.1093/bioinformatics/btt285](https://doi.org/10.1093/bioinformatics/btt285).

[9]

G. Kirov *et al.*, “De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia,” *Mol Psychiatry*, vol. 17, no. 2, pp. 142–153, Feb. 2012, doi: [10.1038/mp.2011.154](https://doi.org/10.1038/mp.2011.154).

[10]

M. F. Egan *et al.*, “Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia,” *Proc. Natl. Acad. Sci. U.S.A.*, vol. 98, no. 12, pp. 6917–6922, Jun. 2001, doi: [10.1073/pnas.111134598](https://doi.org/10.1073/pnas.111134598).

[11]

Multicenter Genetic Studies of Schizophrenia Consortium *et al.*, “Genome-wide association analysis identifies 13 new risk loci for schizophrenia,” *Nat Genet*, vol. 45, no. 10, pp. 1150–1159, Oct. 2013, doi: [10.1038/ng.2742](https://doi.org/10.1038/ng.2742).

[12]

The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, “Genome-wide association study identifies five new schizophrenia loci,” *Nat Genet*, vol. 43, no. 10, pp. 969–976, Oct. 2011, doi: [10.1038/ng.940](https://doi.org/10.1038/ng.940).

[13]

T. Lencz *et al.*, “Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder,” *Nat Commun*, vol. 4, no. 1, p. 2739, Dec. 2013, doi: [10.1038/ncomms3739](https://doi.org/10.1038/ncomms3739).

[14]

D. F. Levinson *et al.*, “Genome-Wide Association Study of Multiplex Schizophrenia Pedigrees,” *AJP*, vol. 169, no. 9, pp. 963–973, Sep. 2012, doi: [10.1176/appi.ajp.2012.11091423](https://doi.org/10.1176/appi.ajp.2012.11091423).

[15]

M. L. Hamshere *et al.*, “Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC,” *Mol Psychiatry*, vol. 18, no. 6, pp. 708–712, Jun. 2013, doi: [10.1038/mp.2012.67](https://doi.org/10.1038/mp.2012.67).

[16]

P. F. Sullivan *et al.*, “Genomewide association for schizophrenia in the CATIE study: results of stage 1,” *Mol Psychiatry*, vol. 13, no. 6, pp. 570–584, Jun. 2008, doi: [10.1038/mp.2008.25](https://doi.org/10.1038/mp.2008.25).

[17]

E. C. del Re *et al.*, “Analysis of schizophrenia-related genes and electrophysiological measures reveals ZNF804A association with amplitude of P300b elicited by novel sounds,” *Transl Psychiatry*, vol. 4, no. 1, pp. e346–e346, Jan. 2014, doi: [10.1038/tp.2013.117](https://doi.org/10.1038/tp.2013.117).

[18]

J. Shi *et al.*, “Common variants on chromosome 6p22.1 are associated with schizophrenia,” *Nature*, vol. 460, no. 7256, pp. 753–757, Aug. 2009, doi: [10.1038/nature08192](https://doi.org/10.1038/nature08192).

[19]

E. H. M. Wong *et al.*, “Common Variants on Xq28 Conferring Risk of Schizophrenia in Han Chinese,” *Schizophrenia Bulletin*, vol. 40, no. 4, pp. 777–786, Jul. 2014, doi: [10.1093/schbul/sbt104](https://doi.org/10.1093/schbul/sbt104).

[20]

J. T. Glessner *et al.*, “Strong synaptic transmission impact by copy number variations in schizophrenia,” *Proc. Natl. Acad. Sci. U.S.A.*, vol. 107, no. 23, pp. 10584–10589, Jun. 2010, doi: [10.1073/pnas.1000274107](https://doi.org/10.1073/pnas.1000274107).

[21]

The International Schizophrenia Consortium, “Common polygenic variation contributes to risk of schizophrenia and bipolar disorder,” *Nature*, vol. 460, no. 7256, pp. 748–752, Aug. 2009, doi: [10.1038/nature08185](https://doi.org/10.1038/nature08185).

[22]

S. Steinberg *et al.*, “Common variant at 16p11.2 conferring risk of psychosis,” *Mol Psychiatry*, vol. 19, no. 1, pp. 108–114, Jan. 2014, doi: [10.1038/mp.2012.157](https://doi.org/10.1038/mp.2012.157).